Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) (FIVE-STAR)
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in Type 2 Diabetes and Chronic Kidney Disease (FIVE-STAR)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Koichi Node, MD, PhD
- Phone Number: +81-952-34-2364
- Email: node@cc.saga-u.ac.jp
Study Locations
-
-
-
Saga, Japan, 849-8501
- Saga University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients who have given their written consent to participate in this study
- Patients who are 20 years of age or older at the time of consent (regardless of gender)
- Patients with type 2 diabetes mellitus
- Patients with chronic kidney disease who meet both of the following criteria; i) eGFR greater than 25 mL/min/1.73 m2 and less than 90 mL/min/1.73 m2, ii) UACR greater than 30 mg/g.cr. and less than 3500 mg/g.cr.
- Patients who have not changed their medications for type 2 diabetes and chronic kidney disease in the past 4 weeks prior to obtaining consent
Exclusion Criteria:
- Patients who are currently taking or have taken MRAs containing finerenone in the past 4 weeks prior to obtaining consent.
- Patients with a history of hypersensitivity to finerenone
- Patients with HbA1c greater than 10%.
- Patients with a serum potassium level of 4.9 mEq/L or higher
- Patients with NYHA class II-IV HFrEF (LVEF <35%)
- Patients with poorly controlled hypertension (e.g., systolic BP >170 mmHg, diastolic BP >110 mmHg, or hypertensive emergencies)
- Patients with a history of ischemic stroke, acute coronary syndrome, cardiovascular surgery or percutaneous intervention, or hospitalization for worsening heart or renal failure in the past 8 weeks prior to obtaining consent
- Patients with a preplanned surgical or percutaneous intervention for coronary artery reconstruction or other cardiovascular disease during the individual observation period.
- Patients with a preplanned treatment such as electrical cardioversion, cardiac resynchronization therapy or pacemaker implantation during the individual observation period.
- Patients with preplanned dialysis or kidney transplantation during the individual observation period.
- Patients with severe hepatic dysfunction (Child-Pugh Class C)
- Patients receiving itraconazole, ritonavir-containing products, atazanavir, darunavir, fosamprenavir, cobicistat-containing products, or clarithromycin, or ensitrelvir
- Patients with Addison's disease
- Patients with active infectious diseases
- Pregnant, possibly pregnant, or lactating patients
- Other patients deemed inappropriate for this study by the principal investigator or subinvestigators (e.g., patients with renal artery stenosis, one kidney, or active malignancy).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Placebo tablets
|
Study participants will be instructed to take either finerenone or placebo orally once daily (preferably at approximately the same time every during the morning).
For study participants with baseline eGFR less than 60mL/min/1.73
m2, the starting dose will be 10mg/day of finerenone (equivalent to 10mg/day in the placebo group), followed by 20 mg/day (equivalent to 20mg/day in the placebo group) approximately 4 weeks after the first dose, in accordance with the latest package insert.
The dose should be increased to 20mg/day (equivalent to 20mg/day in the placebo group) in principle after 4 weeks from the start of the first dose, in accordance with the latest package insert.
Study participants with a baseline eGFR of 60 mL/min/1.73m2
or higher will receive 20mg/day of finerenone (equivalent to 20mg/day in the placebo group) as the starting dose.
|
|
Experimental: Finerenone
Kerendia® tablets
|
Study participants will be instructed to take either finerenone or placebo orally once daily (preferably at approximately the same time every during the morning).
For study participants with baseline eGFR less than 60mL/min/1.73
m2, the starting dose will be 10mg/day of finerenone (equivalent to 10mg/day in the placebo group), followed by 20 mg/day (equivalent to 20mg/day in the placebo group) approximately 4 weeks after the first dose, in accordance with the latest package insert.
The dose should be increased to 20mg/day (equivalent to 20mg/day in the placebo group) in principle after 4 weeks from the start of the first dose, in accordance with the latest package insert.
Study participants with a baseline eGFR of 60 mL/min/1.73m2
or higher will receive 20mg/day of finerenone (equivalent to 20mg/day in the placebo group) as the starting dose.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in CAVI
Time Frame: 24 weeks
|
Change in CAVI at 24 weeks after initiation of protocol treatment compared to baseline
|
24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in UACR
Time Frame: 12 weeks, 24 weeks
|
Proportional changes in geometric mean of UACR at 12 and 24 weeks post-protocol treatment compared to baseline (key secondary endpoint)
|
12 weeks, 24 weeks
|
|
Change in pentosidine
Time Frame: 24 weeks
|
Proportional changes in geometric mean of pentosidine at 24 weeks post-protocol treatment compared to baseline
|
24 weeks
|
|
Change in urinary type IV collagen
Time Frame: 24 weeks
|
Proportional changes in geometric mean of urinary type IV collagen at 24 weeks post-protocol treatment compared to baseline
|
24 weeks
|
|
Change in urinary alpha1-MG
Time Frame: 24 weeks
|
Proportional changes in geometric mean of urinary alpha1-MG at 24 weeks post-protocol treatment compared to baseline
|
24 weeks
|
|
Change in urinary beta2-MG
Time Frame: 24 weeks
|
Proportional changes in geometric mean of urinary beta2-MG at 24 weeks post-protocol treatment compared to baseline
|
24 weeks
|
|
Change in urinary NGAL
Time Frame: 24 weeks
|
Proportional changes in geometric mean of urinary NGAL at 24 weeks post-protocol treatment compared to baseline
|
24 weeks
|
|
Change in urinary NAG
Time Frame: 24 weeks
|
Proportional changes in geometric mean of urinary NAG at 24 weeks post-protocol treatment compared to baseline
|
24 weeks
|
|
Change in urinary L-FABP
Time Frame: 24 weeks
|
Proportional changes in geometric mean of urinary L-FABP at 24 weeks post-protocol treatment compared to baseline
|
24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Koichi Node, MD, PhD, Saga University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Glucose Metabolism Disorders
- Metabolic Diseases
- Urologic Diseases
- Endocrine System Diseases
- Disease Attributes
- Diabetes Mellitus
- Renal Insufficiency
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Diabetes Mellitus, Type 2
- Kidney Diseases
- Renal Insufficiency, Chronic
Other Study ID Numbers
Other Study ID Numbers
- 00002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.